Jim Miller

As offshore savings decline, pharmaceutical companies still have a lot of work to do to reduce costs.

Despite challenges, contract manufacturers in Europe are enjoying considerable success.

Summer deals struck by Novartis and Lilly point to an evolution in contract services.

As offshore savings decline, pharmaceutical companies still have a lot of work to do to reduce costs.

CMC service providers are doing well, but clinical and preclinical CROs are doing even better.

Summer deals struck by Novartis and Lilly point to an evolution in contract services.

CMC service providers are doing well, but clinical and preclinical CROs are doing even better.

Survey results indicate a healthy market, but increasing competition.

Global manufacturing excellence will be a game changer for CMOs that can achieve it.

CMO business models are out of touch with current pharma industry realities. It's time for new thinking.

Global manufacturing excellence will be a game changer for CMOs that can achieve it.

The recent heparin contamination event calls for a new approach to manage a lengthening pharmaceutical supply chain.

CMO business models are out of touch with current pharma industry realities. It's time for new thinking.

The recent heparin contamination event calls for a new approach to manage a lengthening pharmaceutical supply chain.

CMOs have positive outlook for 2008 but are wary of competitive pressures.

Another Asian services provider demonstrates the global nature of pharmaceutical outsourcing.

CMOs have positive outlook for 2008 but are wary of competitive pressures.

The traditional pharmaceutical business model is disintegrating, but the new model is not much different.

Another Asian services provider demonstrates the global nature of pharmaceutical outsourcing.

The dynamics of the R&D pipeline could undercut recent CRO and CMO successes.

The traditional pharmaceutical business model is disintegrating, but the new model is not much different.

Candid comments from a Big Pharma executive highlight the complexity of contract manufacturing.

Contract service providers exist to help clients meet their strategic and financial business objectives. So any prognostication on what the pharmaceutical outsourcing industry will look like in 30 years is really a forecast of the nature and speed of changes in pharmaceutical technologies and business models.

The dynamics of the R&D pipeline could undercut recent CRO and CMO successes.

Could sloppy due diligence practices hurt CMOs and their clients?

Candid comments from a Big Pharma executive highlight the complexity of contract manufacturing.

Contract manufacturers slim down to improve profitability.

Could sloppy due diligence practices hurt CMOs and their clients?

FDA approvals renew the threat of competition from India and China.

Contract manufacturers slim down to improve profitability.